Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/33470
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVRANCKX, Pascal-
dc.contributor.authorValgimigli, Marco-
dc.contributor.authorEckardt, Lars-
dc.contributor.authorLewalter, Thorsten-
dc.contributor.authorUnikas, Ramunas-
dc.contributor.authorMarin, Francisco-
dc.contributor.authorSchiele, Francois-
dc.contributor.authorLaeis, Petra-
dc.contributor.authorReimitz, Paul-Egbert-
dc.contributor.authorSmolnik, Ruediger-
dc.contributor.authorZierhut, Wolfgang-
dc.contributor.authorTijssen, Jan-
dc.contributor.authorGoette, Andreas-
dc.date.accessioned2021-02-16T14:29:37Z-
dc.date.available2021-02-16T14:29:37Z-
dc.date.issued2020-
dc.date.submitted2021-02-16T13:16:13Z-
dc.identifier.citationEUROPEAN HEART JOURNAL, 41 (47) , p. 4497 -4504-
dc.identifier.urihttp://hdl.handle.net/1942/33470-
dc.description.abstractAims To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). Methods and results In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n = 388, VKA n = 389) vs. CCS (edoxaban n = 363, VKA = 366). Participants received edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months, or VKA combined with a P2Y12 inhibitor and aspirin 100 mg (for 1-12 months). The primary bleeding endpoint at 12 months occurred in 59 (15.2%) vs. 79 (20.3%) ACS patients [hazard ratio (HR): 0.73, 95% confidence interval (CI): 0.59-1.02, P = 0.063], and in 69 (19.0%) vs. 73 (19.9%) CCS patients (HR: 0.94, 95%CI: 0.68-1.31, P = 0.708) with edoxaban- and VKA-based therapy, respectively [P for interaction (P-int) = 0.2741]. The main secondary endpoint (composite of CV death, myocardial infarction, stroke, systemic embolic events, or definite stent thrombosis) in ACS patients was 33 (8.5%) vs. 28 (7.2%) (HR: 1.16, 95%CI: 0.70-1.92), compared with 16 (4.4%) vs. 18 (4.9%) (HR: 0.91, 95%CI: 0.47-1.78) CCS patients with edoxaban and VKA-based therapy, respectively (P-int = 0.5573). Conclusions In patients with AF who underwent PCI, the edoxaban-based regimen, as compared with VKA-based regimen, provides consistent safety and similar efficacy for ischaemic events in patients with AF regardless of their clinical presentation.-
dc.description.sponsorshipThis work was supported and funded by Daiichi Sankyo.-
dc.language.isoen-
dc.publisherOXFORD UNIV PRESS-
dc.rightsC The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com-
dc.subject.otherAtrial fibrillation-
dc.subject.otherAnticoagulation-
dc.subject.otherEdoxaban-
dc.subject.otherPercutaneous coronary intervention-
dc.subject.otherAcute coronary syndromes-
dc.subject.otherStable coronary artery disease-
dc.titleEdoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial-
dc.typeJournal Contribution-
dc.identifier.epage4504-
dc.identifier.issue47-
dc.identifier.spage4497-
dc.identifier.volume41-
local.format.pages8-
local.bibliographicCitation.jcatA1-
dc.description.notesVranckx, P (corresponding author), Hasselt Univ, Fac Med & Life Sci, Dept Cardiol & Crit Care Jessaziekenhuis Hasselt, Hasselt, Belgium.-
dc.description.notespascal.vranckx@iccuhasselt.be-
dc.description.otherVranckx, P (corresponding author), Hasselt Univ, Fac Med & Life Sci, Dept Cardiol & Crit Care Jessaziekenhuis Hasselt, Hasselt, Belgium. pascal.vranckx@iccuhasselt.be-
local.publisher.placeGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1093/eurheartj/ehaa617-
dc.identifier.isiWOS:000608409700013-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Vranckx, Pascal] Hasselt Univ, Fac Med & Life Sci, Dept Cardiol & Crit Care Jessaziekenhuis Hasselt, Hasselt, Belgium.-
local.description.affiliation[Valgimigli, Marco] Univ Bern, Bern Univ Hosp, Dept Cardiol, Inselspital, Bern, Switzerland.-
local.description.affiliation[Eckardt, Lars; Lewalter, Thorsten; Goette, Andreas] Atrial Fibrillat Network AFNET, Munster, Germany.-
local.description.affiliation[Eckardt, Lars] Univ Munster, Dept Cardiol & Angiol, Div Electrophysiol, Munster, Germany.-
local.description.affiliation[Lewalter, Thorsten] Hosp Munich South, Dept Cardiol, Munich, Germany.-
local.description.affiliation[Lewalter, Thorsten] Univ Bonn, Bonn, Germany.-
local.description.affiliation[Unikas, Ramunas] Univ Hlth Sci Hosp, Kaunas, Lithuania.-
local.description.affiliation[Marin, Francisco] Hosp Univ Virgen de la Arrixaca, CIBERCV, IMIB Arrixaca, Murcia, Spain.-
local.description.affiliation[Schiele, Francois] Chru Jean Minjoz, Besancon, France.-
local.description.affiliation[Laeis, Petra; Reimitz, Paul-Egbert; Smolnik, Ruediger; Zierhut, Wolfgang] Daiichi Sankyo Europe GmbH, Munich, Germany.-
local.description.affiliation[Tijssen, Jan] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Cardiol, Amsterdam, Netherlands.-
local.description.affiliation[Tijssen, Jan] Cardialysis, Rotterdam, Netherlands.-
local.description.affiliation[Goette, Andreas] St Vincenz Hosp, Dept Cardiol, Paderborn, Germany.-
local.description.affiliation[Goette, Andreas] Univ Hosp Magdeburg, Working Grp Mol Electrophysiol, Magdeburg, Germany.-
local.uhasselt.internationalyes-
item.validationecoom 2022-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.fullcitationVRANCKX, Pascal; Valgimigli, Marco; Eckardt, Lars; Lewalter, Thorsten; Unikas, Ramunas; Marin, Francisco; Schiele, Francois; Laeis, Petra; Reimitz, Paul-Egbert; Smolnik, Ruediger; Zierhut, Wolfgang; Tijssen, Jan & Goette, Andreas (2020) Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. In: EUROPEAN HEART JOURNAL, 41 (47) , p. 4497 -4504.-
item.contributorVRANCKX, Pascal-
item.contributorValgimigli, Marco-
item.contributorEckardt, Lars-
item.contributorLewalter, Thorsten-
item.contributorUnikas, Ramunas-
item.contributorMarin, Francisco-
item.contributorSchiele, Francois-
item.contributorLaeis, Petra-
item.contributorReimitz, Paul-Egbert-
item.contributorSmolnik, Ruediger-
item.contributorZierhut, Wolfgang-
item.contributorTijssen, Jan-
item.contributorGoette, Andreas-
crisitem.journal.issn0195-668X-
crisitem.journal.eissn1522-9645-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
ehaa617.pdfPublished version643.03 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.